Monique Tan

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén et al. · The Lancet · 2017 · 1.3K citations · Full text

Inflammation, Allergy, Lung Inflammation +11

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Dennis M. Black, Ian R. Reid, Steven Boonen et al. · Journal of Bone and Mineral Research · 2011 · 690 citations · Full text

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Reinhard Dummer, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2020 · 397 citations · Full text

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · Journal of Thoracic Oncology · 2021 · 253 citations · Full text